IL37 and psoriasis: In the same year, Krueger et al. [81] assessed the risk of malignancies in patients receiving IL-23 inhibitors (risankizumab, guselkumab, and tildrakizumab) compared to those taking TNF inhibitors (adalimumab, infliximab, etanercept, and infliximab and certolizumab pegol), during the first five years of starting the treatment of psoriasis.